Buzescu Ca has successfully represented Alvogen IPCO S.a.r.l., and Alvogen Romania S.R.L. before the Bucharest Court of Appeals in their challenge to an application by Teva Pharmaceutical Industries Ltd. for a preliminary injunction against the sale of a drug Alvogen distributes.
According to Buzescu Ca, “the scope of the preliminary injunction was to block the sales of Remurel 40 mg/ml, a generic glatiramer acetate drug for the treatment of multiple sclerosis, produced by Synthon BV, and distributed in Romania by Alvogen. Teva previously held an exclusivity position on the market with its innovative glatiramer acetate and 'flagship' drug Copaxone for the treatment of the same disease. According to media reports, global Copaxone sales in the first half of 2018 totaled USD 1.27 billion, which was 36% less than in the corresponding period in 2017, the decrease being mainly the effect of the glatiramer acetate generic entry on the market. The estimated aggregate value of the glatiramer acetate 40 mg/ml market shares in dispute in Romania was around EUR 9 million.”
Buzescu Ca’s team included Senior Partner Peter Buzescu, Partner Adrian Tomescu, Senior Associate Corina Papuzu, and Associate Alex Cretu.
